The drug developer is buying biotechnology firm Synthorx, which focuses on potential cancer treatments, for $2.5 billion. ArQule Inc., up $10.04 to ...
News
- ArQule and Fate Therapeutics soar; Sanofi and Diplomat fall
- Researchers identify top ways to stop projected 142% rise in Latino cancer
26-28, 2020, in San Antonio, is open for registration. ... nursing, dentistry, health professions and graduate biomedical sciences have produced 36,500 ...
- New Menarini CELLSEARCH Studies to be Presented at San Antonio Breast Cancer Symposium
New Menarini CELLSEARCH Studies to be Presented at San Antonio .... biotechnology and diagnostics company headquartered in Florence, Italy, ...
- Stocks are mostly lower on Wall Street with trade in focus
Merck is spending $2.7 billion for ArQule, a small biotechnology company that is still in the earlier stages of studying potential treatments for conditions ...
- Why This Founder Finds Inspiration in a Necklace
I was a month away from finishing a Ph.D. in biomedical engineering from Tufts University. My dad created a personal gift for my sisters and me: ...